A Phase 1 interventional study of MT-7117 in Mild and Moderate Hepatic Impairment, sponsored by Mitsubishi Tanabe Pharma America Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.
Sponsored by Mitsubishi Tanabe Pharma America Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,185 studies in Lymphoma, Follicular with a site in United States — 127 open to participants now, 216 under way, 20 of them phase 3. Lymphoma, Follicular · United States.
Among the 1,185 studies in Lymphoma, Follicular with a site in United States, this one is the 707th largest by enrollment of the 1,015 interventional ones that give a count, is one of 32 that started in 2019, is one of 363 in phase 1, and was the 929th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →127 of the 1,185 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:
University of California, Irvine · Sites in United States
Ages 18+ · Women only
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
New York State Psychiatric Institute · Sites in United States
Ages 22–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 499 · Phase 2 523 · Phase 3 113 · Phase 4 11
First in 1988; this study’s year is marked. 32 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 38 across the 1,015 interventional studies, 74 across the 62 observational. Of the 903 that completed or were terminated, 358 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 1,185 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mitsubishi Tanabe Pharma America Inc., one of the names counted as Tanabe Pharma Corporation. Under that name alone:
Mitsubishi Tanabe Pharma America Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Tanabe Pharma Corporation has 2 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
68 of the studies in Lymphoma, Follicular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT00659035Asokumar BuvanendranUse of Driving Tests to Evaluate Patient Performance on Oral Opioids | 2026-12 |
| NCT06245031Cognito Therapeutics, Inc.Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) | 2026-12 |
Add all 68 to your calendar (.ics) → With an account.
Among the 1,185 studies in Lymphoma, Follicular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MT-7117
Drug: MT-7117
Drug: MT-7117
Single Dose of MT-7117
Maximum observed plasma concentration (Cmax) of MT-7117
Time frame: 0-96 Hours
Area under the plasma concentration time curve from time zero to the time of last quantifiable concentration (AUC0-last) of MT-7117
Time frame: 0-96 Hours
Area under the plasma concentration time curve from time zero to infinity (AUC0-∞) of MT-7117
Time frame: 0-96 Hours
Time to reach maximum plasma concentration (tmax) of MT-7117
Time frame: 0-96 Hours
Plasma terminal elimination half-life (t1/2) of MT-7117
Time frame: 0-96 Hours
Apparent oral clearance (CL/F) of MT-7117
Time frame: 0-96 Hours
Apparent volume of distribution (Vz/F) of MT-7117
Time frame: 0-96 Hours
fraction of unbound drug in plasma or serum (fu) of MT-7117
Time frame: 0-96 Hours
Number of participants with Adverse events (AEs) and Serious Adverse Events (SAEs)
Time frame: 0-96 Hours
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2019 to primary completion in Feb 2021, 18 months.
Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 71. This study's 18 months is below that.
Counting every sponsor, half of 173 studies reached it within 51 months; a quarter within 30 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dersimelagon
Mitsubishi Tanabe Pharma America Inc. →